Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase II, Placebo-controlled Study of Ipatasertib (GDC-0068), an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT01896531 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01896531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01896531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase II, Placebo-controlled Study of Ipatasertib (GDC-0068), an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 14, 2013
Completion date
January 26, 2021
Enrollment
153 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer